View clinical trials related to Pulmonary Cancer.
Filter by:The purpose of this study is to evaluate the overall objective tumor response rate (ORR) of Gefitinib.
Antigenics is enrolling patients in a Phase II study testing the feasibility to derive an autologous investigational vaccine (HSPPC-96) from the tumor tissue of patients with resectable non-small cell lung cancer. Vaccine production will be attempted on all patients who undergo surgery and meet all inclusion/exclusion criteria.